Key Takeaways United Therapeutics (UTHR) reported second-quarter 2025 earnings of $6.41 per share, which missed the Zacks Consensus Estimate of$6.80. However, earnings rose 10% year over year on the back of higher product sales. United Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Tyvaso, Orenitram, Adcirca and Remodulin. It also markets Unituxin for treating pediatric patients with high-risk neuroblastoma. Revenues in the second quarter came in at $798.6 million, beating t ...